[chart]investorshub.advfn.com/uimage/uploads/2017/6/28/lmzwbrabits.jpg[/chart]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CELZ, lets see that screenshot of your reply from them? I bet they were never contacted at all. All is well in CEZL land except for one. :)
CELZ, Ya like getting an engine mechanic to fix your suspension.
Need new Heart call that guy.
Need your Heart Fixed call Timothy.
https://find-a-doctor.cedars-sinai.edu/provider/1114987997-timothy-d--henry
CELZ, Thanks 2019 is gonna be great.
Ur guy is the director of Heart Transplant not Cartology.
Lawrence S. Czer, MD
Medical Director, Heart Transplant Program
Associate Medical Director, Mechanical Circulatory Support Program
Co-Medical Director, Cardiothoracic Surgery Database
Professor, Medicine
http://bio.csmc.edu/view/3512/Lawrence-S-Czer.aspx
CELZ, unproven facts as hearsay. https://find-a-doctor.cedars-sinai.edu/provider/1114987997-timothy-d--henry
Timothy D. Henry, MD
IM/Cardiology
Office: 310-278-3400
Available 24/7: 1-800-CEDARS-1
4.8 / 5
Learn more
Office location
414 N Camden Dr #1100
Beverly Hills, CA 90210
Get Directions
Driving & parking info
Office location
414 N Camden Dr #1100
Beverly Hills, CA 90210
Get Directions
Driving & parking info
SPECIALTY
IM/Cardiology
Provider Info
GENDER
Male
LANGUAGES
English
EXPERIENCE
37 years
Education
University of California, San Francisco School of Medicine
Medical School - Completed 1982
University of Colorado Health Sciences Center
Residency - Completed 1986
University of Minnesota
Fellowship - Completed 1990
University of Minnesota
Fellowship - Completed 1991
Achievements
BOARD CERTIFICATIONS
Board Certified in Internal Medicine
Board Certified in Interventional Cardiology
Board Certified in Cardiovascular Disease
AWARDS & ACTIVITIES
U.S. "Best Doctors" - 2007-16
Master Fellow for Society of Coronary Angiography and Intervention - 2015
Association of University Cardiologists - 2015
Commencement Address Speaker, University of North Dakota School of Medicine & Health Sciences - 2015
American Heart Association’s Annual Heart & Stroke Hero Award in Research - 2013
Minnesota’s 100 Most Influential Health Care Leaders - 2008-12
LUMEN Global Lifetime Achievement Award in Myocardial Infarction - 2012
Patient Ratings & Comments
Learn more
RATINGS
Average Rating:
4.8 / 5
35 Ratings
COMMENTS
By Cedars-Sinai Patienton Aug 20, 2018
Great Medical Experience
By Cedars-Sinai Patienton Aug 20, 2018
I didn't feel rushed. He took time and was very thorough.
By Cedars-Sinai Patienton Jun 27, 2018
If you are looking for a health care provider that truly cares about you and looks out for what is best for you, this is the place to be.
By Cedars-Sinai Patienton Jun 06, 2018
Best hospital complex in LA.
By Cedars-Sinai Patienton May 02, 2018
Great provider
By Cedars-Sinai Patienton May 02, 2018
The best hospital and doctors and staff
By Cedars-Sinai Patienton Mar 07, 2018
no issue
By Cedars-Sinai Patienton Mar 07, 2018
I have mixed feelings about the consultation.
By Cedars-Sinai Patienton Feb 21, 2018
A top notch cardiologist.
By Cedars-Sinai Patienton Feb 14, 2018
I will highly recommend Dr. HENRY AS A CARDIOLOGIST.
By Cedars-Sinai Patienton Feb 14, 2018
Dr Henry is very knoqledgable in his field and communicates to a point where one is very comfortable.
By Cedars-Sinai Patienton Feb 07, 2018
All staff is friendly and efficient.
CELZ, Heart Transplant Director, Really LOL
Lawrence S. Czer, MD
Medical Director, Heart Transplant Program
Associate Medical Director, Mechanical Circulatory Support Program
Co-Medical Director, Cardiothoracic Surgery Database
Professor, Medicine
http://bio.csmc.edu/view/3512/Lawrence-S-Czer.aspx
CELZ, where is the link for proof? Hard to believe without a link. :)
CELZ, DD that will be verified @4pm tomorrow will be up another 25+% :)
CELZ, True Facts :)
TIMOTHY D. HENRY
MD, FACC, MSCAI
Professor of Medicine
Director, Division of Cardiology
Cedars-Sinai Medical Center
Los Angeles, California
Says 2019....2019 Just started Today, How about them apples
https://www.scottsdaleinterventionalforum.com/faculty/timothy-d-henry/
GRDO. Everyone likes a good broth. :)
Bone Broth For Dogs? Here's Why It's A Great Idea!
https://www.dogsnaturallymagazine.com › ... › Remedies › Nutrients And Supplements
Bone broth is one of the most nutritious and delicious foods for dogs. Learn how to make it and why your dog needs it.
GRDO..If You Invested $1 Each in Stocks and Gold in 1801 by 1998 You'd ...
https://me.me/.../if-you-invested-1-each-in-stocks-and-gold-in-35207d31ead946b1b4...
If you invested $1 each in stocks and gold in 1801 by 1998 you'd have over $500K in stock and 78 cents in gold. ... I will soon be a bouillonaire. #UnKNO.
PLSB...Happy New Year.
#1) Break and hold above .001
#2) Take PLSB to the Bank :)
PHIL...Happy New Year. News Soon :)
GRDO, is GREEN that is all that matters. :)
RETC, Strong Close to end the year.
DRUS, 10-K out. 40 min ago. :)
CELZ, I never said it closed at or above a cent. I said closed up 34 + % :)
CELZ, No after hours allowed in the OTC. Still Up over 34% Facts. :)
CELZ, Facts up 34.42% :)
CELZ, Good one. lol
CELZ, Thanks, I didn't have time to upload the new pic in Ihub so I used the one from the other day :)
ARYC, Seems that it was at 11 cents on 7/31 under the same conditions.
Transfer Agent Verified
SEC Loves the SS#'s updates, last was on 12/04
https://www.otcmarkets.com/stock/ARYC/security
ALKM, Thanks but we just had News on the 21st. Longs have more than 1 post. :)
DRUS, Last run to 4 cents 6 months ago. .005 should be easy as Pie. :)
CELZ, Very Nice. :)
CELZ, Just a little:
Keep your eyes on this:
https://clinicaltrials.gov/ct2/show/record/NCT03699943
And latest NEWS:
NEWS
Creative Medical Technology Holdings, Inc. December 2018 Shareholder Update
PHOENIX, Dec. 27, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:
As we end 2018 we look forward to continuing to reach multiple milestones in 2019.
CaverStemTM domestic activities: As previously reported, we are continuing marketing to physicians across the United States. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month.
We anticipate reaching financial self-sufficiency by revenues from sales in 2019.
Physician Marketing Campaigns: Scheduled for release in January 2019, CaverStemTM will begin a series of mailer and email campaigns introducing the CaverStemTM procedure to licensed physicians in the areas of urology, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's our goal to reach out to a minimum of 2500 new physicians each month by these methods.
Brand Awareness to Patients: Scheduled for launch in January 2019, CaverStemTM will increase its online presence on Social Media by sponsorships and banner advertising on websites and search engines attracting the active male. We are currently negotiating an advertising campaign in Los Angeles as our first city to expand into print and radio advertising.
CaverStemTM International: As was announced by publication across social media outlets and our press conference, the company successfully sponsored the treatment of two patients in Moscow using the CaverStemTM procedure. Treatment of patients is ongoing with positive results and is anticipated to steadily increase in 2019. Physicians in Switzerland and Italy are being scheduled for training and patients are being recruited.
CaverStemTM clinical trial: We understand the eagerness to receive published data. We are continuing to work towards this goal of publication of the results as soon as possible.
FemCelzTM; as previously announced, we are progressing with the development of the FemCelzTM procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. We are preparing the patient protocol and designing the website in anticipation of this launch in Q1. Many of our existing CaverStemTM affiliated physician's also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelzTM program.
U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients in the past 90 days with excellent results. By replacing the centrifuge technology with our Generation 2 technology we realize the following benefits;
Reduced bone marrow harvest from 60cc to 20cc.
Higher cell count (less blood harvested).
Reduced procedure time.
Reduced startup cost for physician by eliminating centrifuge.
StemSpineTM: In order to concentrate our efforts on CaverStemTM domestic and international and FemCelzTM, StemSpineTM is expected to launch in late 2019. We feel it is in the best interest of the company to dedicate much of our resources to continue to build those brands and our cash flow before commercializing StemSpine.
AmnioStemTM: We are continuing to accumulate data in order to file for an FDA IND on the use of our amniotic stem cell for the treatment of stroke. We will advise milestones in subsequent filings.
Other patent pending technologies: We continue to prosecute our patent applications with the USPTO.
Acquisitions in 2019: We anticipate acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. in Q1 2019. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStemTM and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStemTM and FemCelzTM brands. The benefit to the company will be
Additional revenue sources from licensing, marketing and administrative fees as allowed for a Medical Service Organization (MSO).
Additional revenue from sale of our medical equipment.
Greater combined brand awareness by cross marketing.
We wish everyone a Happy New Year and the CELZ team will continue to do our best to build the fundamentals of the company, which we believe are stronger than ever.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com. For more information on our CaverStemTM procedure please go to www.caverstem.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
https://c212.net/c/img/favicon.png?sn=AQ11497&sd=2018-12-27 View original content:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-inc-december-2018-shareholder-update-300770932.html
SOURCE Creative Medical Technology Holdings, Inc.
ALKM...CBD Company/Hemp Bill/Makes all the Drinks.
Alkame has been a pioneer in this industry for years and is now one of the country's leading CBD beverage manufacturers. Alkame's wholly owned manufacturing subsidiary, Bell Food & Beverage, will see immediate effects in this burgeoning hemp industry, allowing Bell to produce and ship products across the country with far more certainty and greater clarification regarding the legality of interstate commerce.
"This is great news for the plethora of CBD products and brands, as well as the retail and distribution networks that have been waiting for the rules pertaining to Hemp to be clearly defined on a national level. With these roadblocks now removed, there couldn't be a better time to enter this exploding space," states Alkame CEO, Robert Eakle. Eakle continues, "As a pioneer and leading producer in the CBD beverage industry for quite some time, we are well prepared and have planned ahead in anticipation of its passage by updating our facility and massively increasing our capabilities throughout 2018. In order to accommodate the anticipated growth we've added a new high speed line in conjunction with our original hot and cold fill production lines on the campus, in house lab and formulation, and an endless array of product possibilities. We couldn't be more excited or better positioned to accommodate and assist many more clients in entering this new and emerging sector", and we very much look forward to what's in store for us throughout 2019."
Bell Food and Beverage is a leading manufacturer of natural, organic, specialty food and beverage products, both with and without CBD. Bell utilizes the parent company Alkame's patented water technology. The technology allows for liquid-based products to use an alkaline water base that is not only oxygenated but also micro clustered. Typically, when CBD is consumed as an oil, you only benefit from a small percentage of the ingested amount due to its rather large molecule size. The rest is naturally expelled by your body. Alkame technology allows for water to be infused with CBD using our micro-clustering process and encapsulating the CBD into a water-based formula making it an elite and ideal delivery mechanism for CBD with 100% benefit and significantly increased bio-availability.
"Our product line is extensive. CBD beverages such as waters both natural and flavored, energy drinks, hangover drinks, lemonades, teas, coffees, adult drink mixes and more, to health and beauty products such as lotions, creams, tinctures, salves, and balms, to food items such as CBD enhanced salsas, sauces, condiments and the list goes on," states Bell Food and Beverage, Inc. President Craig Kaufman. Kaufman goes on to say "We are one of the pioneers of this space and we have been in this sector for quite some time, establishing ourselves as a major producer of quality, THC free CBD products. Our patented water technology has certainly given us a strong foothold and head start in this space, and the passage of the Farm Bill has really created a tremendous opportunity for us that we have been preparing for. We couldn't be happier about the passing of the Farm Bill."
About Alkame Holdings, Inc.
Alkame Holdings, Inc. is a publicly traded health and wellness technology holding company, with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly-owned subsidiaries market and distribute enhanced waters utilizing an exclusive patented formula and technology to create enhanced water with several unique properties. The organization is diligently building a strong foundation through the launch and acquisition of appropriate business assets, and by pursuing multiple applications to utilize its Intellectual Property by placement into several emerging business sectors, such as the growing aqua-culture industry, consumer bottled water and RTD products, household pet products, horticulture and agriculture applications, as well as many other various water treatment solutions to both new and existing business platforms.
For more information, visit www.alkameholdingsinc.com.
Alkame Holdings, Inc. Investor Relations
Website: www.alkameholdingsinc.com
Email: info@alkameholdingsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE: Alkame Holdings Inc.
© Copyright 2018 ACCESSWIRE. All Rights Reserved.
https://www.otcmarkets.com/stock/ALKM/news/story?e&id=1249156
BYSD, Maybe we will here something from them on Monday, if the thing is not as stated in the PR.
CELZ...
NEWS
Creative Medical Technology Holdings, Inc. December 2018 Shareholder Update
PHOENIX, Dec. 27, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:
https://www.otcmarkets.com/stock/CELZ/news/story?e&id=1250222
CELZ, We never get Pr's posted on the Hub. They have to pay $200 to post it and the Companies that do are usually trying to sell shares and pay the extra expense. We only get SEC filings posted on Hub. :)
BYSD, expected to be effective on December 29, 2018.
https://www.otcmarkets.com/stock/BYSD/news/Bayside-Corporation-Files-for-1-For-15000-Reverse-Split?id=212027
None of the dates line up with the PD date saying Dec 29th?
30 days from the Filed date would be Jan 20th?
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=053084250205018039094221030124110174181213241041
PHIL, Looks like it is up a nice chunk of change. That I believe. :)
DRUS...News 12/28/2018 1.6 Million Dollars in Contracts.
DRUS, News Within the Past Eleven Days Bantek Inc., through its Subsidiary Howco Distributing Co. Won Approximately 1.6 Million in Contracts with The Federal Government
8:00 AM ET 12/28/18 | BusinessWire
PINE BROOK, N.J.--(BUSINESS WIRE)--December 28, 2018--
Bantek, Inc. (OTCPINK: DRUS) ("Bantek" or the "Company"), a service provider and reseller of drones, insulation jackets and distributor of products to the U.S. Government, today announced that its subsidiary, Howco Distributing ("Howco"), received approximately 1.6 million in contracts in the last eleven days from the US Defense Logistics Agency. In addition, the Howco team visited Columbus, Ohio to explore using a secondary packaging option which will help us package our mid-west and east coast supplier products and visited with the Defense Logistics Land and Maritime contract post-award team and members of the small business administration office.
Michael Bannon, Bantek's Chief Executive Officer, commented, "We are continuously exploring different ways to increase our sales with the U.S. government. When visiting Ohio, we paid a visit to a well-established and capable packing company that can help us more efficiently and at a lower cost package our mid-west and eastern supplier products. We were thoroughly impressed with their operation and we look forward to working with them."
Matt Wiles, Howco's COO stated, "We recently had an excellent visit with the DLA Land and Maritime in Columbus, Ohio including members of the post-award contract team, and members of the small business administration office. These meetings were productive and helped Howco understand how we can better serve the needs of the DLA and support our troops."
Lindsay Somics, Howco's Vice President of Business Development, stated, "During our recent trip to Ohio, we were informed that Howco had a best in class on-time shipping performance rating of 93.4% with the DLA. On-time delivery is something we pride ourselves on and as we grow, to make sure we continue with the pattern we have established we have enlisted a secondary packaging house to support our growing business. This will allow us to reduce freight costs and increase margins on items where we didn't have a competitive edge."
About Howco Distributing Co.
Howco Distributing, a subsidiary of Bantek, Inc., is a premier supplier of spare and replacement parts to a wide variety of Federal Government agencies, U.S. military prime contractors and commercial customers worldwide. Founded in 1990 and located in Vancouver, Washington, Howco's services encompass bid solicitation, contract management, packaging and logistics for construction, transportation, mining and heavy equipment spare and replacement parts to customers worldwide utilizing a wide variety of supply chain solutions. Howco was the winner of 2017 United States Department of Defense Logistics Agency's Commander's Choice Supplier Award and the 2012 United States Department of Defense Logistics Agency's Bronze Supplier Award.
About Bantek, Inc.
Bantek, Inc. (OTCPINK: DRUS), headquartered in Pine Brook, NJ., consists of three separate divisions. First, through Howco Distributing Co., we sell products primarily to U.S. Department of Defense. Second, through Drone USA we sell drone programs, which consists of drones, training, COA's and waivers and other drone-related services, to law enforcement, firefighters, security companies, local, state and our US government. Third, we sell insulation jackets, slates, and insulation services to hospitals, universities, and manufacturers.
Forward-Looking Statements
Certain statements in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include projections of matters that affect revenue, operating expenses or net earnings; projections of growth; and assumptions relating to the foregoing. Such forward-looking statements are generally qualified by terms such as: "plans, "anticipates," "expects," "believes" or similar words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or qualified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. These factors are discussed in greater detail in our Form 10 filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181228005030/en/
CONTACT: Michael Bannon
Chief Executive Officer
mike@bantekinc.com
SOURCE: Bantek, Inc.
Copyright Business Wire 2018
> Dow Jones Newswires
December 28, 2018 08:00 ET (13:00 GMT)